<DOC>
	<DOCNO>NCT00638807</DOCNO>
	<brief_summary>To compare efficacy safety celecoxib versus placebo treatment knee osteoarthritis ( OA ) patient unresponsive prescription strength naproxen ibuprofen could tolerate prescription strength naproxen ibuprofen</brief_summary>
	<brief_title>Safety Efficacy Celecoxib Versus Placebo Treatment Knee Osteoarthritis Patients Who Were Unresponsive Naproxen Ibuprofen</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis , Knee</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Ibuprofen</mesh_term>
	<criteria>Inclusion criterion : Diagnosed , active , symptomatic OA knee flare state functional capacity class IIII baseline visit Failed adequate trial naproxen ibuprofen ( prescription strength ) within past 5 year due lack efficacy , tolerability , ; duration prescription strength ibuprofen naproxen must minimum 2 week drug respective recommend dos failure due lack efficacy , duration failure due lack tolerability Exclusion criterion : Inflammatory arthritis gout/pseudogout acute flare within past 2 year ( subject fibrositis fibromyalgia exclude ) Received acetaminophen within 24 hour baseline visit Use mobility assist device less six week prior study screen use walker History gastrointestinal ( GI ) perforation , obstruction , bleed Diagnosed treated GI ulcer within 60 day prior first dose study medication Received corticosteroid hyaluronic acid within certain timeframe study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>